ASX Share rice
Fri 07 Aug 2020 - 01:32:am (Sydney)

BXN Share Price

BIOXYNE LIMITEDBXNHousehold & Personal Products

BXN Company Information

Name:

Bioxyne Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

50 Clarence Street Sydney NSW Australia 2000

Phone:

61 2 9078 8180

MD, CEO & Director:

Mr. Nam Hoat Chua BA

CFO & Company Sec.:

Mr. Guy Adrian Robertson B.Com., C.A., B.Comm(Hons.), CA, MAICD

Chief Scientific Officer and Director of R&D:

Prof. Margaret Dunkley

Company Overview:

Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. The company operates through Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company's products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink with soy protein and apple fibre, and marine collagen extract for women's weight management; Mustang, a nutritional shake for men's weight management; Mymana, a colostrum and honey based dairy formula product; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, New Zealand, and Asia. Bioxyne Limited is headquartered in Sydney, Australia.

BXN Share Price Information

Shares Issued:

640.15M

Market Capitalisation:

$7.04M

Revenue (TTM):

$2.14M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.002

Profit Margin:

-0.6143

Operating Margin (TTM):

$-0.60

Return On Assets (TTM):

$-0.18

Return On Equity (TTM):

$-0.37

Quarterly Revenue Growth (YOY):

-0.041

Gross Profit(TTM):

$1.21M

Diluted Earnings Per Share (TTM):

$-0.002

BXN CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-172,365

Change To Liabilities:

$100.40K

Total Cashflow From Investing Activities:

$-172,365

Net Income:

$-1,265,882

Total Cash From Operating Activities:

$-1,390,362

Depreciation:

$17.89K

Change To Inventory:

$-84,939

Change To Account Receivables:

$-241,898

Capital Expenditures:

$63.67K

BXN Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-1,265,882

Net Income:

$-1,265,882

Gross Profit:

$1.14M

Operating Income:

$-1,472,803

Total Revenue:

$2.13M

Total Operating Expenses:

$2.62M

Cost Of Revenue:

$0.99M

BXN Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$92.05K

Total Liabilities:

$829.32K

Total Stockholder Equity:

$3.09M

Other Current Liabilities:

$8.04K

Total Assets:

$3.97M

Common Stock:

$62.18M

Other Current Assets:

$36.26K

Retained Earnings:

$-59,196,768

Good Will:

$151.18K

Other Assets:

$61.78K

Cash:

$1.77M

Total Current Liabilities:

$829.32K

Property - Plant & Equipment:

$108.78K

Net Tangible Assets:

$2.81M

Total Current Assets:

$3.52M

Net Receivables:

$759.13K

Short-Term Investments:

$451.96K

Inventory:

$713.62K

Accounts Payable:

$433.32K

Non Currrent Assets (Other):

$451.96K

Short-Term Investments:

$451.96

Non Current Liabilities Total:

$0

BXN Share Price History

BXN News

26 Apr, 2020
Bioxyne Limited (ASX:BXN) shareholders should be happy to see the share price up 22% in the last month. But in truth...
27 Feb, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
10 Dec, 2019
In 2017 Nam Chua was appointed CEO of Bioxyne Limited (ASX:BXN). This analysis aims first to contrast CEO compensation...
25 Oct, 2019
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
20 Sep, 2019
Bioxyne Limited (ASX:BXN) continues its loss-making streak, announcing negative earnings for its latest financial year...